Medivir Logo

Medivir

Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.

MVIR | ST

Overview

Corporate Details

ISIN(s):
SE0000325151 (+4 more)
LEI:
549300VWDGUX0WMJ1T79
Country:
Sweden
Address:
Box 1086, 141 22 Huddinge
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Medivir is a clinical-stage pharmaceutical company focused on developing innovative treatments for cancer. The company concentrates its research and development on oncology, specifically targeting cancers with high unmet medical needs where patients have few therapeutic options. Medivir's business strategy relies heavily on collaborations with academic and industrial partners to leverage specialized knowledge and advance its projects. Through this partnership-driven approach, the company has previously succeeded in taking products from research through clinical development to global launch. Its pipeline includes the development of novel tumor-directed therapies such as oral prodrugs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-18 18:19
Major Shareholding Notification
Swedish 10.3 KB
2025-11-14 08:30
Regulatory News Service
Medivir offentliggör informationsdokument avseende företrädesemission
Swedish 55.9 KB
2025-11-14 08:30
Regulatory News Service
Medivir publishes disclosure document regarding rights issue
English 57.5 KB
2025-11-10 15:00
Post-Annual General Meeting Information
BULLETIN FROM EXTRAORDINARY GENERAL MEETING in MEDIVIR AB (PUBL)
English 51.4 KB
2025-11-10 15:00
Post-Annual General Meeting Information
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I MEDIVIR AB (PUBL)
Swedish 51.2 KB
2025-11-06 08:30
Quarterly Report
Swedish 391.5 KB
2025-11-06 08:30
Quarterly Report
English 332.8 KB
2025-10-23 08:30
M&A Activity
Medivir tecknar exklusivt licensavtal med Biossil, Inc. för remetinostat
Swedish 50.3 KB
2025-10-23 08:30
M&A Activity
Medivir enters exclusive licensing agreement with Biossil, Inc. for remetinostat
English 49.9 KB
2025-10-08 09:15
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Medivir AB (publ)
Swedish 80.7 KB
2025-10-08 09:15
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting of Medivir AB (publ)
English 82.0 KB
2025-10-08 08:52
Share Issue/Capital Change
Medivir beslutar om en fullt garanterad företrädesemission motsvarande cirka 15…
Swedish 81.6 KB
2025-10-08 08:52
Share Issue/Capital Change
Medivir announces a fully guaranteed rights issue of approximately SEK 151 mill…
English 81.3 KB
2025-08-21 08:30
Interim Report
Swedish 392.4 KB
2025-08-21 08:30
Interim Report
English 331.5 KB

Automate Your Workflow. Get a real-time feed of all Medivir filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medivir

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medivir via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-11-15 Fredrik Öberg Other Buy 100,000 77,000.00 SEK
2022-11-14 Jens Anders Fredrik Lindberg Other Buy 250,000 192,500.00 SEK
2022-11-14 Magnus Christensen Other Buy 150,000 115,500.00 SEK
2022-03-28 Jens Anders Fredrik Lindberg Other Buy 15,000 122,850.00 SEK
2022-03-25 Jens Anders Fredrik Lindberg Other Buy 10,000 80,000.00 SEK
2022-03-03 Magnus Christensen Other Buy 6,000 46,800.00 SEK
2021-12-23 Malene Jensen Other Buy 15,000 25,650.00 SEK
2021-12-13 Malene Jensen Other Buy 50,000 109,500.00 SEK
2021-12-13 Malene Jensen Other Buy 50,000 85,500.00 SEK
2021-05-13 Fredrik Öberg Other Buy 97,500 97,500.00 SEK

Peer Companies

HVIVO PLC Logo
A CRO running human challenge trials to test infectious disease vaccines for pharma/biotech clients.
United Kingdom
HVO
Iconovo AB Logo
Develops inhaled therapies and patented dry powder inhalers for global pharma partners.
Sweden
ICO
IMMUPHARMA PLC Logo
Develops novel peptide therapeutics for autoimmune diseases like Lupus (SLE) and CIDP.
United Kingdom
IMM
Inhalation Sciences Sweden AB Logo
Inhalation research instruments and CRO services for preclinical pharma/biotech development.
Sweden
ISAB
Initiator Pharma A/S Logo
Clinical-stage firm developing drugs for nervous system disorders like ED & trigeminal neuralgia.
Denmark
INIT
IXICO PLC Logo
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom
IXI
J. Molner AS Logo
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia
JML
LYSOGENE Logo
France
LYS
Mazaro N.V. Logo
Engineering patented, high-efficiency transmissions for vehicles and industrial drivelines.
Belgium
MLMAZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.